We are live on ! Find out more
SRDX

Surmodics

Delisted

SRDX was delisted on the 18th of November, 2025.

147 hedge funds and large institutions have $677M invested in Surmodics in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 49 increasing their positions, 53 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 7

7% more funds holding

Funds holding: 138147 (+9)

0.46% more ownership

Funds ownership: 89.55%90.01% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

2% less capital invested

Capital invested by funds: $691M → $677M (-$13.6M)

8% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 53

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1.24M

Holders
147
Holders Change
+9
Holders Change %
+6.52%
% of All Funds
2.55%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
49
Reduced
53
Closed
7
Calls
Puts
$1.24M
Net Calls
-$1.24M
Net Calls Change
+$888K

SRDX Hedge Fund Activity: Q2 2021 in Review

147 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Surmodics (SRDX) for Q2 2021, worth a combined $677M — down 2% from $691M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new SRDX positions and 7 closed out — a net gain of 9 holders — while 49 added to existing stakes and 53 trimmed.

The largest buyer was Soleus Capital Management, adding an estimated $6.81M. The largest seller was BlackRock, cutting an estimated $4.57M.

  • 147 institutional investors held Surmodics (SRDX) as of Q2 2021, up from 138 in Q1 2021.
  • Funds reported $677M of Surmodics stock for Q2 2021, down 2% quarter-over-quarter.
  • 16 funds opened new Surmodics positions in Q2 2021 and 7 closed out, a net change of +9 holders.
  • The largest Surmodics buyer in Q2 2021 was Soleus Capital Management, an estimated $6.81M added.
  • The largest Surmodics seller in Q2 2021 was BlackRock, an estimated $4.57M sold.

Based on aggregated 13F filings for Q2 2021.